Experimental Drug Gets Tested for Severe TBI
Researchers from the University of Cincinnati’s Department of Surgery, Division of Trauma and Critical Care, are now participating in a national clinical trial of an experimental drug to stop blood clot formation in victims of severe TBI. The drug known as Transexamic Acid (TXA) has the potential to save lives and improve outcomes. TXA will be administered to the treatment group once at the scene of the incident and again in the Emergency Department. A comparison group will receive just one dose at the scene, and the control group will receive only salt water.